The Netherlands: Gilde kicks off GHPE IV with Sanquin Reagents acquisition

Specialist healthcare investor, Gilde Healthcare, plans to acquire Sanquin Reagents from Sanquin Health Solutions (SHS) as the first investment from its €517m private equity fund (GHPE IV) that closed in March 2022. Financial terms are yet to be disclosed. Sanquin Reagents produces and sells blood group and immune reagents, materials needed for diagnostic research and…

You must be a HMI Subscriber to view this content.

Subscribe Now »